5 Key Takeaways

• 1

  Molecular diagnostics face barriers like data harmonization and funding, impacting precision medicine's adoption in oncology.

• 2

  Education is crucial for clinicians and pathologists to understand molecular testing's value and its evolving role in cancer care.

• 3

  Budget allocation must prioritize precision medicine to ensure effective biomarker testing and support pathology laboratories.

• 4

  Liquid biopsy complements tissue diagnostics, requiring harmonization and pharmaceutical support for broader adoption in oncology.

• 5

  Monitoring with liquid biopsy can detect mutations early, influencing treatment decisions and improving patient outcomes.